Baird Starts Myovant Sciences Ltd. (MYOV) at Outperform

November 21, 2016 6:45 AM EST
Get Alerts MYOV Hot Sheet
Price: $11.35 -4.7%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade MYOV Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Baird initiates coverage on Myovant Sciences Ltd. (NYSE: MYOV) with a Outperform rating and a price target of $20.00.

Analyst Brian Skorney commented, "Myovant's lead asset, relugolix, in-licensed from Takeda in April, draws similarities to AbbVie's/Neurocrine's potential blockbuster, elagolix. Relugolix has a few potential advantages over existing therapies, a validated mechanism of action, and eyes set on three significant market opportunities. With the drug entering global Phase 3 trials in the next few months and Japanese Phase 3 data expected in 2H17 from licensor Takeda, 2017 could be a pivotal year for Myovant. We are initiating at a $20 price target."

For an analyst ratings summary and ratings history on Myovant Sciences Ltd. click here. For more ratings news on Myovant Sciences Ltd. click here.

Shares of Myovant Sciences Ltd. closed at $11.25 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, New Coverage

Related Entities

Robert W Baird

Add Your Comment